I wonder one question which i didnt manage to google. NGS is actively used for cancer research, but is there any rule or recommendation for the allele frequency cutoff of the somatic mutation detected by NGS data to be clinically significant like in case of sanger sequencing (where mutation is supposed to be clinically significant with allele frequency of 15 or higher as i know). As i know there should be sufficiant amount of cells hurboring driver mutation for it to be targetable by drugs or any other invasion. Or in case of NGS statistical significance is enough?
Thanks in advance for the answer